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Vancomycin resistant Enterococcus (VRE) colonized patients are likely to receive VRE targeted Gram-positive antibiotics
and may not be de-escalated appropriately once final cultures are available. A retrospective cohort study was
conducted in VRE-colonized and non-VRE colonized patients with Enterococcal bloodstream infections. Of 101
patients (n = 50 VRE-colonized; n = 51 non-colonized), empiric therapy with linezolid or daptomycin was started
more often in VRE-colonized than non-colonized patients (n = 8, 15.5% vs n = 27, 54%, p < 0.01). There was no
difference in de-escalation once VRE infection was ruled out (non-colonized, n = 2, 66.7% vs VRE-colonized, n = 2,
50%, p = 0.09). This study encourages continued stewardship vigilance to decrease inappropriate antibiotic use.
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Enterococcus is a common cause of nosocomial infections,
and the incidence of vancomycin resistant Enterococcus
(VRE) infection continues to rise [1,2]. Patients with
VRE infection incur an increased cost of care of $27,
190 compared to patients with vancomycin-susceptible
Enterococcus (VSE) infection [3]. Additionally, patients
with an Enterococcal bloodstream infection (BSI) who
are VRE-colonized frequently receive empiric Gram-
positive antibiotics targeted against VRE, such as linezo-
lid or daptomycin. Finalized cultures growing VSE may
warrant appropriate antibiotic de-escalation, which is a
critical stewardship issue. Unnecessary linezolid and
daptomycin use has been associated with increasing
emergence of linezolid and daptomycin resistant VRE
strains and represents a significant public health prob-
lem [4,5]. We sought to determine the percent of pa-
tients with an Enterococcal BSI initially started on
linezolid or daptomycin whose therapy was de-escalated
once finalized culture data is available.* Correspondence: milgriff@nmh.org
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A retrospective cohort study was conducted at Northwestern
Memorial Hospital in Chicago, IL. Patients >18 years of
age with at least one positive blood culture for Entero-
coccus spp., identified between January 1, 2010 and De-
cember 31, 2011, that was treated as an active infection by
the attending physician were evaluated for inclusion in the
study. Patients were excluded if the attending physician
elected not to treat the positive blood culture as an ac-
tive infection or if the patient had a polymicrobial BSI.
Only the first positive blood culture per patient during
the study period was included. VRE colonization status
was determined by active surveillance or previous docu-
mented VRE infection. Active surveillance is employed
via rectal swab upon admission and then weekly in
high-risk units including intensive care (medical and
surgical), hematology and oncology, and transplant
(solid organ and bone marrow) per the infection control
and prevention departmental protocol. The Northwestern
University and Midwestern University Institutional Review
Boards approved this study.
Patients were stratified into two groups, VRE-colonized
and non-VRE colonized. The primary outcome studied
was the percent of patients with an Enterococcal BSI ini-
tially started on linezolid or daptomycin whose therapy
was de-escalated once VRE infection was ruled out. Thetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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VRE, percent of patients with neutropenia, and incidence
of sepsis and death. Continuous variables were evaluated
with the Student’s t-test, and categorical variables were
evaluated with the Chi-square or Fisher’s Exact test as ap-
propriate. All tests were two tailed with p < 0.05 considered
significant. Data analysis was performed using Intercooled
Stata, version 12 (StataCorp LP, College Station, TX).
Findings
A total of 162 patients were identified and considered for
inclusion from January 1, 2010 to December 31, 2011. Of
the 162 patients, 61 patients did not meet inclusion due to:
polymicrobial BSI (73%), the attending physician did not
treat the positive blood culture as an active infection (18%),
age under 18 years (5%), and culture determined to be con-
tamination (4%). Therefore, 101 patients were included in
the analysis (n = 50 VRE-colonized; n = 51 non-colonized).
VRE-colonized patients were younger than non-colonized
patients (57.8 years vs. 66.1 years, p < 0.01). There were
no differences in gender, race, infection source, or the
place from which the patient was admitted to the hospital
(p > 0.05 for all). Empiric therapy with linezolid or dapto-
mycin was started more often in VRE-colonized than non-
colonized patients (54%, n = 27 vs. 15.5%, n = 8; p < 0.01;
Table 1). There were eleven non-colonized patients with
VRE BSI, eight of which were initiated on VRE therapy be-
fore susceptibilities and 42 VRE-colonized patients with
VRE BSI, 27 of which were initiated on VRE therapy before
susceptibilities. There were eight non-colonized patients
who empirically received linezolid or daptomycin, and
two of the three patients that could be de-escalated
were de-escalated. There were 27 colonized patients
that empirically received linezolid or daptomycin and two
of the four that could be de-escalated were de-escalated.Table 1 Primary and secondary outcomes of patients with
enterococcal BSI
Non-colonized VRE-colonized p-value




8 (15.6) 27 (54) <0.01
Could be de-escalated (n, %) 3 (37.5) 4 (14.8) 0.31
De-escalated (n, %) 2 (66.7) 2 (50) 0.09
Secondary outcomes
VRE BSI (n, %) 11 (21.5) 42 (84) <0.01
E. faecium (n, %) 17 (33.3) 42 (84) <0.01
Neutropenia (n, %) 3 (5.9) 16 (32) <0.01
Transplant (n, %) 7 (13.7) 19 (38) <0.01
Sepsis (n, %) 19 (37.2) 27 (54) 0.09
Mortality (n, %) 10 (19.6) 11 (22) 0.78For the primary outcome, there was no difference between
the groups in de-escalation once VRE was ruled out (50%,
n = 2 in the colonized group vs. 66.7%, n = 2 in the non-
colonized group; p = 0.99). VRE-colonized patients were
more likely to have VRE BSI (p < 0.01), neutropenia
(p < 0.01), or a transplant (p < 0.01). There was no differ-
ence between the groups regarding sepsis (p = 0.09) and
mortality (p = 0.78).
Discussion
Our study found that the incidence of VRE BSI was sig-
nificantly greater in the VRE-colonized group compared
to the non-colonized group. While approximately half of
the VRE-colonized patients were empirically started on li-
nezolid or daptomycin, only 50% of those eligible were ap-
propriately de-escalated. This poses a potential risk for
antibiotic resistance and supports the need for continued
stewardship vigilance. Inappropriate use of antibiotics with
VRE activity may perpetuate resistance; therefore appro-
priate de-escalation is critical [6].
Our study supports reports that patients with an
Enterococcal BSI with neutropenia or a transplant who
are VRE-colonized are at a higher risk of VRE infection
than non-colonized patients [7,8]. Yeh et al found that
patients with severe illness, prolonged hospitalization,
surgical exploration, and frequent use of antibiotics are
at high risk for VRE infections [9]. Empiric linezolid or
daptomycin for Enterococcal BSI in these patients may
be therefore warranted until VRE is ruled out; however,
sepsis was not a risk factor for VRE infection.
Limitations for this study should be acknowledged. This
was a retrospective cohort study and is subject to the bias
associated with this study design. The study was limited to
a single institution with small number of patients eligible
for de-escalation; however, these stewardship issues are
likely to be generalizable to other institutions.
VRE-colonized patients were more likely to be empir-
ically stared on linezolid or daptomycin to cover VRE.
This study encourages continued stewardship vigilance
to decrease inappropriate antibiotic use. Further study is
warranted to address this important antimicrobial stew-
ardship issue.
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